Selexis Announces Promotion of Ms. Regine Brokamp to Chief Operating Officer
Geneva, Switzerland, January 7, 2009
Selexis SA, a Swiss-based biotechnology company offering technologies and services enabling improved drug discovery, development, and cGMP production, announced today the promotion of Ms. Regine Brokamp to Chief Operating Officer.
“On behalf of the Selexis Board of Directors, I am very pleased to announce the promotion of Regine Brokamp to the position of Chief Operating Officer” said Dr. Igor Fisch, CEO of Selexis SA. “Regine has been instrumental in the maturation of our growing organization and been highly active in the successful expansion of our SURE cell line development service programs.”
“Among her many responsibilities, one of her most important jobs will be leading our Operational Excellence program. Operational Excellence is an extremely important program at Selexis, especially as we continue to expand our outsourcing partnerships with big pharma and leading biotech’s. We are very happy that Regine will be taking on more responsibilities in our rapidly growing organization”.
Dr. Fisch continues, “Above all, we firmly believe our clear leadership position is a direct result of our innovative and efficient technologies, allowing Selexis to offer state-of-the-art service programs and hiring and promoting the right people”.
In Ms. Brokamp’s new position, she will be fully responsible for all operations at Selexis SA.
About Selexis:
Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services enabling significant reductions in the time, effort and costs associated with the generation mammalian cell lines expressing pharmaceutically relevant proteins (i.e. targets, MABs, rProteins).
The Selexis technology portfolio (Selexis Genetic Elements™, Selexis SUREtech Vectors™ and Selexis SURE Cell Line Development Procedures™) is based on the discovery and application of unique genetic elements that control the dynamic organization of chromatin within all mammalian cells. Based on the Selexis technologies, production CHO cell lines were developed and are being used to produce proteins under clinical evaluation.
The Selexis SURE Cell Line Development Service℠ program provides biopharma and pharma companies with an outsourcing partner capable of efficiently managing the rapid development of high-performance cell lines used in preclinical screening or low cost clinical and commercial production. Enabled by the Selexis technologies, production CHO cells lines have been developed and are achieving production titers of greater than 31 grams per liter.
Selexis Genetic Elements™, Selexis SUREtech Vectors and SURE Cell Line Development℠ are trademarks of Selexis SA.
For more information:
SELEXIS SA
Andrew F. Sandford
Vice President of Business Development
(617) 595-5769
andrew.sanfordATselexis.com